Payment Issues Could Limit HPV Vaccine Use

BY DAMIAN MCNAMARA Miami Bureau

JACKSONVILLE, FLA. — Financial and logistic barriers will limit the implementation and impact of human papillomavirus vaccine, Dr. Lance Rodewald said at a conference on STD prevention sponsored by the Centers for Disease Control and Prevention.

New vaccines incorporated into the child immunization schedule are typically adopted quickly across the nation. "For adolescents, we don't do as well," Dr. Rodewald said. "For example, there is 74% coverage for the three shots for hepatitis B. It is better for MMR and Td [tetanusdiphtheria], but our adolescent platform is not well established now."

To improve distribution to those at highest risk, primary care physicians and ob.gyns. will be encouraged to join the federal government's Vaccines for Children (VFC) program. VFC pays for vaccinations for certain vulnerable children through age 18 years, including those on Medicaid, Native Americans or Alaska natives, the uninsured, and those insured without a vaccine benefit.

Underinsured children are not covered by VFC, nor are they covered in most cases by a smaller federal program—Section 317—or state funding.

"HPV [human papillomavirus] vaccine is certainly going to be delivered in a twotiered system. There is no way around it unless something changes," said Dr. Rode-

HSV-2 Not Likely To Be a Cervical Cancer Cofactor

ATLANTA — Herpes simplex virus-2 does not appear to be a cofactor of human papillomavirus in the development of cervical cancer, Dr. Manuela Zereu reported at the annual meeting of the American Society of Clinical Oncology.

Human papillomavirus (HPV) is well established as an infection that is central to the pathogenesis of invasive cervical cancer, but because many women with HPV do not develop this cancer, it is believed certain cofactors play a role in disease development.

Some studies have suggested HSV-2 is one such cofactor, and in vitro experiments have shown a synergistic interaction between HSV-2 and HPV, but the findings of the current study did not bear this out, Dr. Zereu of the Santa Casa Cancer Center in Porto Alegre, Brazil, said in a poster presentation.

For the study, paraffin-embedded tissue samples from 229 patients diagnosed with adenocarcinoma of the uterine cervix between 1995 and 2003 were tested. DNA extraction showed that HPV was present in 79% of specimens, including HPV-18 in 51% of cases and HPV-16 in 34% of cases. However, all samples were negative for HSV-2 DNA.

—Sharon Worcester

wald, a pediatrician and director of the Immunization Services Division, National Immunization Program, at the Centers for Disease Control and Prevention.


Because of inadequate state and Section 317 funding, many states cannot purchase vaccine for underinsured children, resulting in the two-tiered policy.

"There is some indication the president might increase funding to include underinsured children who could get vaccinated at federal public health sites—but it's unlikely to happen this year," he said.

Financing the HPV vaccine for women over age 18 is another challenge. "The provider may have to purchase adult vaccines up front and get reimbursed later. So there is a financial risk if the vaccine is not used," Dr. Rodewald said.

The financial considerations are not unique to HPV prevention. Other new vaccines likely to come soon include a second-dose varicella product and protection against shingles/postherpetic neuralgia, Dr. Rodewald said. "These new vaccines are great, but they come at a cost," he said. The cost to protect each child has grown from \$45 in 1985 to \$155 in 1995 to \$837 in 2006.

"The U.S. immunization system is highly effective and highly successful at protecting children from vaccine-preventable diseases," Dr. Rodewald said. "But the most important stress in the U.S. system is financing access to the many new vaccines."



Levernir is indicated for once- or twicedaily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hymerotypemia

Important safety information Levemir should not be diluted or mixed with any other insulin preparations.

hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the mcst common adverse effect of all insulin therapies, including Levemir. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Levemir is not to be used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or longacting insulin preparations. The dose of Levemir may need to be adjusted in patients

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients

Please see brief summary of Prescribing Information on adjacent page FlexPen and Levemir are registered trademarks of Novo Nordisk A/S.



